Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.

ABSTRACT:

Background

Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients.

Methods

The study included a total of 82 recurrent glioblastoma patients treated with bevacizumab combination therapy whom were both response and biomarker evaluable. Gene expression of tumor tissue was analyzed by using a customized NanoString platform covering 800 genes. Candidate gene predictors associated with response were analyzed by multivariate logistic and Cox regression analysis.

Results

Two genes were independently

SUBMITTER: Urup T 

PROVIDER: S-EPMC5423207 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature